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ABSTRACT
Advancement in science and technology has brought a remarkable change in therapy of cancer. Particles are engineered in such a way so that they are 
attracted to diseased cells, which allow direct treatment of cancer cells. Drug delivery systems control the location in the body where it is released 
and the rate at which a drug is released. Conventional chemotherapeutic possesses some serious side effects, including damage of the immune system 
and other various types of organs with rapidly proliferating cells due to non-specific targeting, lack of solubility, and inability to enter the core part of 
the tumor which results in impaired treatment with the reduced dose and low survival rate. Nanoparticles can be programmed in such a way so that 
it can recognize the cancerous cells by giving selective and accurate drug delivery avoiding interaction with the healthy cells. The main aim of this 
review focuses on various strategies for cancer cell targeting. It also discusses specific drug delivery by nanoparticles inside the cells, illustrating many 
successful researches in the field of cancer therapy.
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INTRODUCTION
Cancer is a group of diseases that lead to abnormal cell growth that has 
a high potential to invade other parts of the body [1]. The uncontrolled 
proliferation of the cancer cells makes treatment process more tedious 
and more complex. Various methods such as radiation, chemotherapy, 
removal by surgical methods, and hormone therapy have been 
employed to treat cancer. It is important to take care that the drugs made 
for the treatment should have ability to differentiate the cancer cells 
and normal cells. Hence, in the modern scientific era, the techniques 
of polymer chemistry and engineering are used to target the specific 
cancer cells in the body. Conventional chemotherapeutic drugs fail to 
target the cancer cells selectively. Following reasons provide a brief 




active drug agents may result in disorderly pharmacokinetics, which 
results in larger than necessary doses that ultimately increase 
toxicity [2,3].
•	 Traditional	 chemotherapeutic	agents	often	get	washed	out	 from	
the circulation being engulfed by macrophages though they remain 
in the circulation for a very short time and cannot interact with the 
cancerous cells making the chemotherapy completely ineffective.
•	 Poor	solubility	of	drugs.
•	 Chemotherapeutic	agents	often	cannot	penetrate	and	reach	the	core	
of solid tumors, failing to kill the cancerous cells.
Nanotechnology is the application of materials, primitive structures, 
devices, or systems at the molecular, atomic, or macromolecular scales. 
The nanoparticles size ranges from 1 to 100 nanometre(nm). Nanoscale 
assays can contribute to cost saving in screening campaigns [4]. 
Nanomaterials are different from other materials due to the two major 
factors: The increased surface area and quantum effects. These factors 
are responsible to enhance the properties such as strength, electrical 
characteristics, reactivity, and in vivo behavior. Few advantages of 
targeted drug delivery system using nanoparticle is shown in Fig. 1.
Nanotechnology in cancer is being implemented for the diagnosis, 
detection, and treatment of cancer. It plays an important role in overcoming 
many of the problems that conventional methods face in the treatment, 
diagnosis, and detection of cancer [5]. Various research is being carried 
out to discover more accurate nanotechnology-based cancer treatment 
and to minimize the side effects of the conventional methods of treatment.
CANCER TARGETING METHODS
The delivery of the drug to the cancer cells can be achieved primarily by 
two methods - active and passive methods (Fig. 2).
ACTIVE TARGETING
Active targeting is usually achieved by conjugating the nanoparticle 
to a targeting moiety where chemotherapeutic agents carried by 
nanoparticles are designed in such a way as they directly interact with 
the infected cells in the body. Nanoparticles bear some certain functional 
characteristics. The surface of the nanoparticles consists the essential 
functional group to bind to target cancer cells receptors. In active targeting, 
the nanoparticles are designed to target the cancerous cells, either 
by ligand-receptor interaction or antibody-antigen recognition [6-8]. 
Polymers, lipids, ceramics, and metals are being currently used to 
construct the nanoparticles. Natural and synthetic polymers and lipids 
are typically used as drug delivery vectors [9-11]. Due to the invading 
nature of our immune system, the nanoparticles carrying the drugs get 
engulfed by the phagocytes and macrophages. To avoid the engulfing of 
these nanoparticles, the polymer coating technology has been developed. 
Polymer contains both hydrophobic and hydrophilic regions. The 
hydrophilic polymer coating on the nanoparticle surface repels plasma 
proteins and makes it able to escape from being opsonized and cleared. 
This is called as a “cloud” effect [12-15].
The active targeting is particularly attractive for the intracellular 
delivery of macromolecular drugs such as deoxyribonucleic acid, 
small interfering ribonucleic acid, and proteins. The enhanced cellular 
internalization rather than an increased tumor accumulation is 
responsible for the anticancer efficacy of actively targeted nanocarriers. 
This is the base of the design of delivery systems targeted to endocytosis-
prone surface receptors [16].
Receptor targeting
Various nanocarrier with the targeting receptors and targeting ligands 
along with the type of cancer is given in Table 1. Receptor targeting 
methods are of various types.
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Epidermal growth factor receptor (EGFR)
It is a transmembrane protein that is a receptor for members of the 
epidermal growth factor family (EGF family: A family of tyrosine kinase 
receptors)	of	extracellular	protein	ligands	[17].	When	these	receptors	
get stimulated, they activate the key processes involved in tumor 
growth and progression, including angiogenesis, invasion, proliferation, 
and metastasis. Various types of therapeutic approaches are aimed at 
the EGFR. The EGFR receptors are stimulated when the ligand does not 
bind to it. The binding of ligand inactivates these receptors which will 
ultimately lead to cell proliferation. Some of the monoclonal antibody 
(mAb) inhibitors such as cetuximab and panitumumab help in stopping 
the binding of receptor-specific ligands to receptors. The mAbs are 
carried along with nanoparticles (liposomes) to the sites, and it blocks 
the	extracellular	ligand	binding	domain.	With	the	binding	site	blocked,	
signal molecules can no longer attach there and activate the tyrosine 
kinase.
Folate receptor
Folate receptors are responsible for binding of folate (ligand) 
and reduce the folic acid derivatives and mediate the delivery of 
tetrahydrofolate to the interior of the cells through receptor-mediated 
endocytosis.	 The	 alpha	 isoform,	 folate	 receptor-α,	 is	 overexpressed	
in	40%	of	human	 cancers.	 In	 contrast,	 folate	 receptor-β	 is	 expressed	
on activated macrophages and also on the surfaces of malignant cells 
of hematopoietic origin [18]. Utilizing the concept, researchers are 
designing the surface of nanoparticles with folic acid [19-21]. Russell-
Jones et al. examined the potential of using folic acid as a targeting agent 
for the delivery of poly(N-(2-hydroxypropyl) methacrylamide (HPMA) 
conjugated daunomycin in four murine tumor models. It was found that 
the tumor-bearing mice injected with daunomycin HPMA conjugates 
survived more and a number of survivors got increased. The method 
states that folic acid can be important in enhancing the efficacy of other 
polymer-bound cytotoxins. Other strategies include:
•	 Folate-linked	methotrexate	dendrimers.
•	 Folate	 conjugated	 covalently	 using	 surface	 carboxyl	 groups	 as	
well	as	conjugation	of	folate	to	hydrazine	modified	polylactic	acid	
nanoparticles (isobutyl-cyanoacrylate nanocapsules used).
The transferrin (Tf) receptor
It is a type of glycoprotein needed for the import of iron into the cell and 
is	 regulated	 in	 response	 to	 intracellular	 iron	 concentration.	With	 the	
increase in the receptor expression, the cell proliferation will be higher. 
The transferrin receptor that import iron inside the cell is activated 
in a higher speed that results in greater uptake and leads to rapid 
cell proliferation which is almost 100 times higher than the normal 
activation in normal cells. Its extracellular accessibility and ability 
to internalize and its central role in the cellular pathology of human 
cancer make this receptor an attractive target for cancer therapy [22-
24]. Various approaches have been given by different researchers. 
Tf can be conjugated to a variety of materials for cancer targeting 
which include a Tf-chemotherapeutic agent, Tf-toxic protein, Tf-
RNases (ribonucleases), Tf antibody, and Tf peptide [25,26]. Similarly, 
Kawamoto et al. worked on Tf -lytic hybrid peptide increased the death 
efficiency of cancer cells by 80%.
Asialoglycoprotein receptors
The asialoglycoprotein receptors are lectins which bind 
asialoglycoprotein (glycoproteins from which a sialic acid has been 
removed to expose galactose residues). Lectins are proteins of non-
immunological origin, which have an ability to recognize and bind to 
carbohydrate moieties attached to glycoproteins expressed on the 
cell surface. Asialoglycoprotein is overexpressed in hepatoma, which 
is utilized in cancer targeting using nanoparticles for anticancer drug 
delivery. Lectins can be incorporated into nanoparticles as targeting 
moieties that are directed to cell surface carbohydrates [27]. Sung et al. 
prepared poly(--glutamic acid)-poly (lactide) block copolymers loaded 
with paclitaxel using the emulsion solvent evaporation technique. 
These nanoparticles inhibited the growth of the cells with a consequent 
decrease in systemic toxicity.
Antibody mediated
Highly specific mAbs are used to boost up the immune response and 
to intensify the immune system’s antitumor capacity. These types of 
antibodies target proteins that are abnormally expressed in neoplastic 
cells. Nanoparticles conjugated with an antibody against a specific 
tumor antigen are developed for selective drug delivery. Nowadays, 
hybridoma technology has resulted in the therapy of various diseases. 
These antibodies are highly specific, and when it is targeted by the drug, 
it binds to the specific infected cancer cells.
Fig. 1: Advantages of targeted drug delivery system using 
nanoparticles
Fig. 2: The active and passive methods of targeting
Table 1: Various targets and the respective ligands along with nanocarrier
Nanocarrier Targets/targeting ligands Tumor cells References
Liposomes Tf receptor/Tf C6 glioma [28]
Micelles liposomes Asialoglycoprotein receptor/lectins, galactosamine HepG2 B16 melanoma [29,30]
Liposomes micelles Folate receptor/folate Human KB [31,32]
Liposomes EGRF receptor/anti-EGRF Mab MDA-MB-468, U87 glioma [33]
Magnetic nanoparticles VEGF/anti-VEGF mAb Human liver cancer [34]
VEGF: Vascular endothelial growth factor, mAb: Monoclonal antibody, EGRF: Epidermal growth factor
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The hybridoma cell results from the fusion of a myeloma and an 
antigenically stimulated normal plasma cell to bind specifically to tumor 
cell antigens. Myeloma cells are used to produce the mAbs. mAbs destroy 
the cancer cells by the variety of approaches which include directly 
inducing apoptosis, blocking growth factor receptors, and anti-idiotype 
formation. It has the ability to totally eradicate cancer cells by activating 
complement-mediated cellular cytotoxicity and antibody-dependent 
cell-mediated	 cytotoxicity.	 Wartlick	 et al. constructed a biodegradable 
nanoparticle based on human serum albumin and gelatin in the covalent 
attachment of the biotin-binding protein NeutrAvidin, enabling the 
binding of biotinylated drug targeting ligands by avidin-biotin complex 
formation. Human EGFR 2 (HER2) receptor-specific antibody trastuzumab 
(Herceptin) was conjugated to the surface of these nanoparticles to target 
HER2-overexpressing cells. Confocal laser scanning microscopy method 
showed an effective internalization of these nanoparticles by HER2-
overexpressing cells through receptor-mediated endocytosis [35].
Antiangiogenesis
Angiogenesis is the physiological process through which new blood 
vessels form of pre-existing vessels [36-38]. Angiogenesis is a normal 
and vital process in growth and development as well as in wound 
healing. It also helps in the formation of granulation tissue. Cancerous 
cells produce abnormal amounts of angiogenic growth factors resulting 
in an excessive angiogenesis overwhelming the effects of natural 
angiogenesis inhibitors giving rise to leaky and tortuous vessels that 
are in a constant state of inflammation [39-43].
Inhibition of the vascular endothelial growth factor (VEGF) pathway 
has become the focus of angiogenesis research. Approximately 60% of 
malignant tumors express high concentrations of VEGF. During tumor 
growth, the action of angiogenesis stimulators surpasses the control of 
angiogenesis inhibitors, allowing for less regulated blood vessel growth 
and formation.
Active targeting of the tumor vasculature can be achieved by targeting 
the VEGF receptors with nanoparticles. The first angiogenesis inhibitor 
for colorectal cancer therapy, bevacizumab (Avastin), an anti-VEGF 
mAb that inhibits the growth factor of new blood vessels was approved 
in 2004 [44,45]. Prokop et al. constructed a hydrophilic core of 
sodium alginate, cellulose sulfate, and antiangiogenic factors such as 
thrombospondin-1 which was cross-linked with dextran polyaldehyde 
with calcium chloride or conjugated to heparin sulfate with sodium 
chloride. In addition, bioluminescent agent called luciferase was placed 
within the polyanionic core. Targeted nanoparticles were evaluated by 
monitoring luciferase in a murine model.
PASSIVE TARGETING
In passive targeting, nanoparticles accumulate mostly in the neoplastic 
tissues which result in enhanced permeability and retention (EPR) 
phenomenon. All nanocarriers use the EPR effect as a guiding principle.
The EPR effect is now becoming the most valuable or we can say the gold 
standard in cancer-targeting drug designing. Passive targeting consists in 
the transport of nanocarriers through leaky tumor capillary fenestrations 
into the tumor interstitium (composed of a collagen network and a gel-
like fluid) and cells by convection or passive diffusion [46]. The EPR 
effect will be optimal if nanocarriers can evade immune surveillance 
and circulate for a long period. Very high concentrations of drug-loaded 
nanocarriers can be achieved at the tumor site, for instance, 10–50-fold 
higher than in normal tissue within 1–2 days [47].







uptake and homogenous distribution of drugs in the tumor [49].
Prevention from lysosomal degradation
Lysosomal enzymes have the capability to destroy both the 
nanoparticles	 and	 drugs	 inside	 the	 cells.	When	 the	 nanotool	 usually	
reach the lysosomal compartment, in which the hydrolytic enzymes 
are present have the ability to degrade the nanocarrier and the drug 
carried by the nanocarrier. Therefore, the intracellular distribution of 
the carrier is modified when the encapsulated drug is a nucleic acid.
Recent studies with different targeting agents, drugs used, and 
type of nanoparticle
Table 2 gives the various investigations in the field of drug delivery to 
cancer cells using nanotech methods.
CONCLUSIONS
From the above study, we can conclude that recent methods of drug 
delivery using nanotechnology methods have enriched the field of 
medicine in cancer treatment. This has significantly lowered the number 
of cancer suffering patients in hospitals and reliable cost treatment 
process with low side effects. The process is highly being used in the 
selective recognizing of the cancerous cells, targeted drug delivery, and 
overcoming limitations of the conventional chemotherapies. Various 
methods are already marketed, and some process is in the phase of 
clinical trials and research. The two methods active and passive can be 
used to reduce the disadvantages of chemotherapeutic drugs. Although 
day by day new type cancers are being found, the nanotechnology can 
fulfill the wish and hope of patience for living the long life.
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